260 related articles for article (PubMed ID: 22356350)
1. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
Derendorf H; Munzel U; Petzold U; Maus J; Mascher H; Hermann R; Bousquet J
Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350
[TBL] [Abstract][Full Text] [Related]
2. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
Bousquet J; Bachert C; Bernstein J; Canonica GW; Carr W; Dahl R; Demoly P; Devillier P; Hellings P; Fokkens W; Klimek L; Lieberman P; Meltzer E; Price D; Ryan D; Wahn U
Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125
[TBL] [Abstract][Full Text] [Related]
3. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.
Meltzer EO; LaForce C; Ratner P; Price D; Ginsberg D; Carr W
Allergy Asthma Proc; 2012; 33(4):324-32. PubMed ID: 22856633
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis.
Carr WW; Ratner P; Munzel U; Murray R; Price D; Canonica GW; Mullol J; Virchow JC; Lieberman P; Meltzer E; Bachert C
Allergy Asthma Proc; 2012; 33(6):450-8. PubMed ID: 23127291
[TBL] [Abstract][Full Text] [Related]
5. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
Meltzer E; Ratner P; Bachert C; Carr W; Berger W; Canonica GW; Hadley J; Lieberman P; Hampel FC; Mullol J; Munzel U; Price D; Scadding G; Virchow JC; Wahn U; Murray R; Bousquet J
Int Arch Allergy Immunol; 2013; 161(4):369-77. PubMed ID: 23652808
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
Klimek L; Bousquet J; Price D
Expert Opin Drug Saf; 2016 Jan; 15(1):117-29. PubMed ID: 26581312
[TBL] [Abstract][Full Text] [Related]
7. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
Berger WE; Shah S; Lieberman P; Hadley J; Price D; Munzel U; Bhatia S
J Allergy Clin Immunol Pract; 2014; 2(2):179-85. PubMed ID: 24607046
[TBL] [Abstract][Full Text] [Related]
8. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis.
Kortekaas Krohn I; Callebaut I; Alpizar YA; Steelant B; Van Gerven L; Skov PS; Kasran A; Talavera K; Wouters MM; Ceuppens JL; Seys SF; Hellings PW
Allergy; 2018 May; 73(5):1084-1093. PubMed ID: 29121401
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia.
Ilyina NI; Edin AS; Astafieva NG; Lopatin AS; Sidorenko IV; Ukhanova OP; Khanova FM
Int Arch Allergy Immunol; 2019; 178(3):255-263. PubMed ID: 30677766
[TBL] [Abstract][Full Text] [Related]
10. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial.
Berger W; Sher E; Gawchik S; Fineman S
Allergy Asthma Proc; 2018 Mar; 39(2):110-116. PubMed ID: 29490769
[TBL] [Abstract][Full Text] [Related]
11. Deposition characteristics of a novel intranasal formulation of azelastine hydrochloride plus fluticasone propionate in an anatomic model of the human nasal cavity.
Meltzer EO; Bachert C; Mayer MJ; Kopietz F; Koltun A; Maus J; D'Addio AD
Allergy Asthma Proc; 2020 Jul; 41(4):265-270. PubMed ID: 32393418
[No Abstract] [Full Text] [Related]
12. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
Carr W; Bernstein J; Lieberman P; Meltzer E; Bachert C; Price D; Munzel U; Bousquet J
J Allergy Clin Immunol; 2012 May; 129(5):1282-1289.e10. PubMed ID: 22418065
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis.
Ratner PH; Hampel F; Van Bavel J; Amar NJ; Daftary P; Wheeler W; Sacks H
Ann Allergy Asthma Immunol; 2008 Jan; 100(1):74-81. PubMed ID: 18254486
[TBL] [Abstract][Full Text] [Related]
14. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis.
Price D; Shah S; Bhatia S; Bachert C; Berger W; Bousquet J; Carr W; Hellings P; Munzel U; Scadding G; Lieberman P
J Investig Allergol Clin Immunol; 2013; 23(7):495-503. PubMed ID: 24654314
[TBL] [Abstract][Full Text] [Related]
15. Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups.
Berger WE; Fineman SM; Lieberman P; Miles RM
Ann Allergy Asthma Immunol; 1999 Jun; 82(6):535-41. PubMed ID: 10400480
[TBL] [Abstract][Full Text] [Related]
16. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
Ridolo E; Montagni M; Melli V; Bonzano L; Incorvaia C; Canonica GW
Ther Deliv; 2015; 6(6):653-9. PubMed ID: 25913181
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate.
Derendorf H; Meltzer EO; Hermann R; Canonica GW
Drugs Today (Barc); 2014 Jan; 50(1):15-31. PubMed ID: 24524103
[TBL] [Abstract][Full Text] [Related]
18. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
[TBL] [Abstract][Full Text] [Related]
19. Intranasal spray medications for maintenance therapy of allergic rhinitis.
Berger WE; Meltzer EO
Am J Rhinol Allergy; 2015; 29(4):273-82. PubMed ID: 26132312
[TBL] [Abstract][Full Text] [Related]
20. Escaping the trap of allergic rhinitis.
Rossi O; Massaro I; Caminati M; Quecchia C; Fassio F; Heffler E; Canonica GW
Clin Mol Allergy; 2015; 13(1):17. PubMed ID: 26244040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
